Boehringer Ingelheim recently announced the start of the THULITE phase II clinical study ( NCT06962839 ). THULITE will ...

EYP-1901 shows promising results in reducing treatment burden for diabetic macular edema, offering sustained improvements in ...

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance ...

LumiThera’s PBM is the only device that has demonstrated meaningful vision improvement compared to baseline for people living ...

Both 6-month trials were randomized, controlled studies that evaluated PER-001 delivered in a slow-release, dissolvable ...

The company notes that the workforce reduction is expected to provide annual cash compensation cost savings of approximately $15 million and offsets additional expenses expected based on the ...